Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable new treatment option for patients with B-cell malignancies. However, by applying selective pressure, outgrowth of antigen-negative tumor cells can occur, eventually resulting in relapse. Subsequent rescue by admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Roex, Gils, Campillo-Davo, Diana, Flumens, Donovan, Shaw, Philip Anthony Gilbert, Krekelbergh, Laurens, De Reu, Hans, Berneman, Zwi N., Lion, Eva, Anguille, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919645/
https://www.ncbi.nlm.nih.gov/pubmed/35287669
http://dx.doi.org/10.1186/s12967-022-03326-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919645/
https://www.ncbi.nlm.nih.gov/pubmed/35287669
http://dx.doi.org/10.1186/s12967-022-03326-6

Ejemplares similares